Immunitybio Inc (IBRX) Shares Outstanding 2013–TTM

Name: Immunitybio Inc (IBRX) shares outstanding history 2013-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-10

Immunitybio Inc annual shares outstanding for fiscal TTM was 1,050 million shares, an increase of 14.1% from 920 million shares in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

IBRX Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Shares Outstanding (M)	1,050M	920M	700M	509M	400M	389M	383M	383M	325M	322M	328M	286M	316M	316M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IBRX Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Shares Outstanding (M)	1,050M	1,027M	990M	947M	888M	853M	735M	698M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Shares Outstanding at Comparable Companies

SYRE Shares Outstanding — Spyre Therapeutics Inc.
CRNX Shares Outstanding — Crinetics Pharmaceuticals Inc
PCVX Shares Outstanding — Vaxcyte Inc
IMVT Shares Outstanding — Immunovant Inc
TGTX Shares Outstanding — TG Therapeutics Inc

More IBRX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All IBRX financial statements → Interactive IBRX charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.